Therapeutic DNP derivatives and methods using same
The present invention includes DNP derivatives of formula (I) that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.
1. A method of ameliorating a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of hypertriglyceridemia, fatty liver, and insulin resistance, the method comprising administering to the subject a therapeutically effective amount of 2,4-dinitrophenyl methyl ether or a solvate thereof.
2. The method of claim 1 , wherein the therapeutically effective amount of the 2,4-dinitrophenyl methyl ether or solvate thereof is about 25 μmoles/kg.
3. The method of claim 1 , wherein the method further comprises administering to the subject at least one additional therapeutic agent.
4. The method of claim 3 , wherein the 2,4-dinitrophenyl methyl ether, or solvate thereof, and the at least one additional therapeutic agent are co-administered to the subject.
5. The method of claim 4 , wherein the 2,4-dinitrophenyl methyl ether, or solvate thereof, and the at least one additional therapeutic agent are co-formulated.
6. The method of claim 1 , wherein the subject is a mammal.
7. The method of claim 6 , wherein the mammal is human.
8. A method of increasing energy expenditure in a subject m need thereof, the method comprising administering to the subject a therapeutically effective amount of 2,4-dinitrophenyl methyl ether, or a solvate thereof, whereby energy expenditure in the subject is increased and wherein the subject is afflicted with at least one disease or disorder selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatic steatosis, type 2 diabetes (T2D), acquired lipodystrophy, lipodystrophy (inherited), partial lipodystrophy, hypertriglyceridemia, obesity, metabolic syndrome, Rett's syndrome, Friedreich's ataxia, and insulin resistance.
9. The method of claim 8 , wherein the therapeutically effective amount of the 2,4-dinitrophenyl methyl ether, or solvate thereof, is about 25 μmoles/kg.
10. The method of claim 8 , wherein the subject is a mammal.
11. The method of claim 10 , wherein the mammal is human.